FDA 483 - Gadal Laboratories Inc. - April 28, 2016
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Gadal Laboratories Inc., an OTC drug manufacturer in Miami, FL, revealed significant deficiencies across its production, quality, and materials systems. The firm lacked validated manufacturing processes, analytical methods, and cleaning procedures, and failed to adequately review discrepancies or conduct required annual product reviews. Additionally, the purified water system was not routinely tested for conformance, indicating a broad failure to ensure drug product quality and purity.
ID · d3d5f494-7bcf-47a9-b56f-e89798e49607